Daniel J. O'Connor - 12 Dec 2022 Form 4 Insider Report for ZyVersa Therapeutics, Inc. (ZVSA)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ZVSA
Reported as of: 12 Dec 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Dec 2022, 18:21:31 UTC
Prior SEC filing: 02 Jun 2022
Next SEC filing: 03 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Daniel J. O'Connor

Key filing fact

Daniel J. O'Connor filed Form 4 for ZyVersa Therapeutics, Inc. (ZVSA) on 14 Dec 2022.

Key facts

This page summarizes Daniel J. O'Connor's Form 4 filing for ZyVersa Therapeutics, Inc. (ZVSA).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 14 Dec 2022, 18:21.

Change

Previous filing in this sequence was filed on 02 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZVSA transaction

Common Stock

Other

Transaction value: $0
Shares: +1,377,598
Change %
Price: $0.000000
Shares after: 1,377,598
Date: 12 Dec 2022
Ownership: See Footnote
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZVSA transaction Derivative

Series A Convertible Preferred Stock

Other

Transaction value
Shares: +1,750
Change %
Price
Shares after: 1,750
Date: 12 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,750
Exercise price: $10.00
Footnotes: F1, F2, F4, F5

ZVSA transaction Derivative

Warrant (right to buy)

Other

Transaction value
Shares: +1,750
Change %
Price
Shares after: 1,750
Date: 12 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,750
Exercise price: $11.50
Footnotes: F1, F2, F5, F6

ZVSA transaction Derivative

Warrant (right to buy)

Other

Transaction value: $0
Shares: +177,204
Change %
Price: $0.000000
Shares after: 177,204
Date: 12 Dec 2022
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 177,204
Exercise price: $11.50
Footnotes: F1, F2, F3, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The Issuer completed a business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.

Footnote F2

The securities were previously securities of Larkspur but were converted automatically to securities of the Issuer in connection with the transactions contemplated by the Business Combination Agreement.

Footnote F3

The securities are held of record by Larkspur Health LLC (the "Sponsor"). Daniel J. O'Connor is the sole manager of Larkspur Health LLC and in such capacity has voting and investment discretion with respect to the common stock held of record by Larkspur Health LLC. By virtue of this relationship, Mr. O'Connor may be deemed to have beneficial ownership of the securities held of record by the Sponsor. Mr. O'Connor disclaims any such beneficial ownership except to the extent of his pecuniary interest.

Footnote F4

The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.

Footnote F5

Mr. O'Connor paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5.

Footnote F6

The warrant is immediately exercisable in full.